Caution is Needed in Designing Pharmacy Coverage. by Farmer, Steven A & Borden, William B
Caution is Needed in Designing Pharmacy Coverage
Steven A. Farmer, MD, PhD; William B. Borden, MD
P harmaceuticals are a critical component of modernmedical care and have contributed substantially to health
and quality of life. They are also expensive, accounting for
10% of US health care costs.1 By the end of this year,
Medicare beneficiaries are expected to spend $343 billion on
medications, and drug spending is projected to grow faster
than both the inpatient and outpatient care categories.2
Commercial and public payers use a range of mechanisms to
constrain these costs, including formularies, tiered copay-
ments, and preauthorization. These coverage policies may
have potent impacts on medication usage, and their effects
deserve close scrutiny. In the current issue of the journal, Li
et al examine the impact of the Medicare prescription drug
program on the use of statin medications.3 The researchers
exploit the unusual design of the Medicare program to assess
how changing copayments impact both therapeutic substitu-
tion and medication discontinuation.
At its inception, the Medicare program was designed to
provide catastrophic coverage to hospitalized elderly Ameri-
cans. As beneficiary survival increased over time, the
emphasis shifted toward management of chronic disease.4
Yet, for its first 38 years, the program included no prescrip-
tion drug benefit. The Medicare Modernization Act of 2003
established the Medicare prescription drug program (known
as Medicare Part D), and coverage began in 2006.5 The drug
program added a major new entitlement for Medicare
beneficiaries, the cost of which was shared between bene-
ficiaries and taxpayers. Even so, the plan struggled to balance
the desire for comprehensive coverage with the need for cost
containment.6 As a compromise, comprehensive coverage
was established for indigent patients, while most beneficiaries
faced significant coverage gaps. After meeting the $250
deductible, participating nonindigent patients were responsi-
ble for 25% of drug costs up to $2250, but then were
responsible for all costs until they reached the “catastrophic”
limit of $5100 (Table 1). This coverage gap between $2250
and $5100 became colloquially known as the “donut hole.”
Although many seniors benefited financially from the program,
its unusual design imposed predictable financial shocks for
patients with multiple chronic conditions.
Using a 5% random sample of administrative claims drawn
from the Medicare Chronic Condition Warehouse in 2006, the
researchers identify patients taking branded Lipitor (atorvas-
tatin) and Crestor (rosuvastatin) at the beginning of 2006 and
assess whether they converted to a generic alternative or
discontinued treatment. In a difference-in-differences model,
their analysis compares patients who were subject to generic-
only gap coverage (study group) to propensity-matched, low-
income subsidy patients (LIS; control group). They find that
study patients decreased branded statin use by 12%, and that
these declines were only partially offset by new generic statin
prescriptions. Relative to controls, the coverage gap was
associated with reductions in mean monthly 30-day fills of any
statin (0.18; CI, 0.23, 0.13) and any lipid-lowering drug
(0.17; CI, 0.22, 0.12). The researchers conclude that
increased copayments caused some patients to switch from
branded to generic statins, whereas others discontinued them
altogether.
The study has a number of limitations. First, to be included
in the analysis, all patients spent more than $2250 on
medications in 2006, suggesting that they were sicker than
Table 1. Medicare Part D 2006 Program Design for Patients
With Incomes Greater Than 135% of the Federal Poverty Line
Drug Expenditure ($) Patient (%) Medicare (%)
0 to 250 100 0
251 to 2250 25 75
2251 to 5100 100 0
Over 5100 5 95
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excluded patients. Patients may respond differently to
copayments depending on their health status. Second, the
researchers appropriately used difference-in-differences
methods for the study, but they use propensity scores to
match patients who were subject to the coverage gap with LIS
patients who were not. Although they incorporate area-level
median household income as a matching criteria, by defini-
tion, LIS patients (less than $12 123 for individuals and
$16 362 for a couple) have incomes well below their area
median household income ($30 387).6 The study and control
groups are highly likely to respond differently to copayment
changes.7 As a sensitivity analysis, the researchers also
compare the study group to non-LIS patients who were not
subject to the coverage gap and find similar results. However,
non-LIS (wealthier) patients who were not subject to the
coverage gap voluntarily enrolled in the most costly plans and
may have also responded differently to copayment changes.
Finally, patients subject to the coverage gap may have elected
to purchase branded statins internationally, but were unable
by statute to use Medicare prescription drug coverage to pay
for them. Administrative claims only document prescriptions
for which a bill was paid, and the impact of international
purchasing is unknown.
This study adds to a body of literature that finds that
patients respond to financial incentives.1 Prescription drug
insurance coverage generally increases use of prescription
drugs and decreases cost-related nonadherence.8,9 Con-
versely, cost-sharing policies may decrease pharmaceutical
expenditures, but may have unintended consequences on
the use of other health services and on care outcomes.10 It is
precisely the unintended consequence of a payment policy
decreasing adherence of a proven beneficial treatment that
Li et al have studied with statin prescriptions. The benefits of
statins in preventing cardiovascular events are convincingly
demonstrated in multiple, large, randomized, controlled
trials11 and supported epidemiologically by observational
decreases in cardiovascular events concordant with decreases
in population cholesterol.12 Moreover, the abrupt discontinu-
ation of statins after myocardial infarction may have detri-
mental effects beyond simply the absence of statins.13 Li et al
have linked a policy feature, namely, the increase in copay-
ments for branded statins, to an overall decrease in statin
prescriptions even when a generic alternative was available.
Although Li et al effectively use a natural experiment to
show that payment policy can adversely impact evidence-
based medication adherence, a number of subsequent
developments have decreased the impact of the Medicare
Part D design. First, coverage revisions have substantially
decreased financial shocks within the donut hole (see
Table 2).14 Second, drug cost transparency is much greater
today for both patients and providers. Ambulatory electronic
health record adoption has increased from around 25% in
2006 to greater than 75% in 2014,15 and many systems
display insurance copayment tier levels at the point of
prescribing. Patients and their providers are now better able
to make informed and shared decisions in the exam room
about medications that fit the patient’s medical and financial
needs.
Drugs make an increasingly important contribution to
health care outcomes, and drug coverage policies aim to
contain costs while improving value. Ideally, coverage deci-
sions should discourage low-value drug prescribing, encour-
age selection of low-cost drug options where they exist, and
encourage evidence-based prescribing. However, policies are
written to apply to all patients, and individual patient
circumstances may vary. Although conversion of branded to
generic formulations of the same drug makes sense in nearly
all circumstances, the therapeutic substitution to another
drug in the same class, as promoted by tiered copayments, is
more problematic. In particular, statin drugs vary substantially
in potency, a factor explicitly recognized in current treatment
guidelines.16 They are also metabolized differently, have
different half-lives, and vary in chemical characteristics, such
as lipophilia. These drug reimbursement policies may increase
drug-drug interactions and prompt safety concerns.17 Statin
side effects are also unfortunately common and may be
idiosyncratically specific to individual drugs.18
Although tiered pharmacy pricing coverage is common-
place, the design of the original Part D program placed the
greatest financial burden on the sickest patients, and in the
face of sharp copayment increases, some patients choose to
forgo statins altogether. Notably, a recent economic simula-
tion based on the MI-FREE study suggests that the opposite
approach may actually be cost saving.19 The study found that
following a myocardial infarction, provision of free evidence-
based medications, including statins, would increase survival
by 0.14 quality-adjusted life years and decrease overall per-
patient costs by $4011. They project that the policy would
save $2 billion annually if nationally implemented.
Given the very legitimate variations in the needs of
individual patients and the fact that many patients will
ultimately defer to their clinicians’ judgment, policies directed
to the prescriber may be more appropriate. Prescribers are
Table 2. Medicare Part D 2017 Program Design for Patients
With Incomes Greater Than 135% of the Federal Poverty
Line14
Drug Expenditure ($) Patient (%) Medicare (%) Discount (%)
0 to 400 100 0 0
401 to 3700 25 75 0
3701 to 4950 40 10 50
Over 5100 5 95 0
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better positioned to make informed trade-offs between costs
and outcomes than many patients are. Immediate and
effortless availability of patient-specific drug formulary
options and pricing is an important step toward achieving
greater value. Efforts to hold prescribers accountable for
generic prescribing rates, overall pharmacy costs, and patient
outcomes at the population level also have merit. Population-
level accountability avoids the administrative inefficiencies of
preauthorization programs and allows prescribing flexibility
for individual patients. This approach is increasingly promi-
nent in emerging payment reforms, including the landmark
Medicare Access and Children’s Health Insurance Program
(CHIP) Reauthorization Act legislation.20
The growth of US health care spending is unsustainable,
and effective solutions are needed to improve value. Drug
spending is increasingly contributing to the cost of care, and
policies are needed to manage pharmacy utilization. Whereas
large patient pharmacy copayments almost certainly impact
drug utilization, they may be counterproductive if they
decrease use of evidence-based therapies. Policy makers
should pay careful attention to program designs to avoid
unintended consequences like those demonstrated in the
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